Biophysics of the SERCA2A/DWORF Complex, Implications for Treatment of Heart Failure

被引：0
|
作者：
Li, Ang [1 ]
Stroik, Daniel [1 ]
Schaaf, Tory [1 ]
Yuen, Samantha [1 ]
Kleinboehl, Evan [1 ]
Cornea, Razvan L. [1 ]
Thomas, David D. [1 ]
机构：
[1] Univ Minnesota, Biochem Mol Biol & Biophys, Minneapolis, MN USA
来源：
BIOPHYSICAL JOURNAL | 2020年 / 118卷 / 03期
关键词：
D O I：
暂无
中图分类号：
Q6 [生物物理学];
学科分类号：
071011 ;
摘要：
2897-Pos
引用
收藏
页码：593A / 593A
页数：1
相关论文
共 50 条
  • [31] SERCA2a gene transfer improves diastolic function in ischemic heart failure
    Ishikawa, K.
    Tilemann, L.
    Ladage, D.
    Fish, K.
    Kawase, Y.
    Hajjar, R.
    EUROPEAN HEART JOURNAL, 2011, 32 : 791 - 791
  • [32] SERCA2a: its role in the development of heart failure and as a potential therapeutic target
    Fragoso-Medina, Jorge
    Zarain-Herzberg, Angel
    RESEARCH REPORTS IN CLINICAL CARDIOLOGY, 2014, 5 : 43 - 54
  • [33] SERCA2a microdomain cAMP changes in heart failure with preserved ejection fraction
    Gotthardt, Michael
    Lehnart, Stephan E.
    CARDIOVASCULAR RESEARCH, 2024, 120 (03) : 220 - 222
  • [34] Stabilisation of SR Leak in Heart Failure After SERCA2a Gene Therapy
    Lyon, A. R.
    Bannister, M. L.
    Kohlbrenner, E.
    Hajjar, R. J.
    Harding, S. E.
    Macleod, K. T.
    HUMAN GENE THERAPY, 2010, 21 (04) : 503 - 503
  • [35] SERCA1a can functionally substitute for SERCA2a in the heart
    Ji, Y
    Loukianov, E
    Loukianova, T
    Jones, LR
    Periasamy, M
    AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY, 1999, 276 (01): : H89 - H97
  • [36] Value of SERCA2a as a Biomarker for the Identification of Patients with Heart Failure Requiring Circulatory Support
    Ezzitouny, Meryem
    Rosello-Lleti, Esther
    Portoles, Manuel
    Sanchez-Lazaro, Ignacio
    Arnau-Vives, Miguel Angel
    Tarazon, Estefania
    Gil-Cayuela, Carolina
    Lozano-Edo, Silvia
    Lopez-Vilella, Raquel
    Almenar-Bonet, Luis
    Martinez-Dolz, Luis
    JOURNAL OF PERSONALIZED MEDICINE, 2021, 11 (11):
  • [37] Correcting Calcium Dysregulation in Chronic Heart Failure Using SERCA2a Gene Therapy
    Samuel, T. Jake
    Rosenberry, Ryan P.
    Lee, Seungyong
    Pan, Zui
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2018, 19 (04)
  • [38] Istaroxime follow-on compounds: A new class of selective SERCA2a activators for chronic heart failure treatment
    Arici, Martina
    Hsu, Shih-Che
    Ferrandi, Mara
    Barassi, Paolo
    Ronchi, Carlotta
    Torre, Eleonora
    Luraghi, Andrea
    Metallo, Alessia
    Chang, Gwo-Jyh
    Ferrari, Patrizia
    Bianchi, Giuseppe
    Regonesi, Maria Elena
    Airoldi, Cristina
    Peri, Francesco
    Zaza, Antonio
    Rocchetti, Marcella
    VASCULAR PHARMACOLOGY, 2024, 155
  • [39] SERCA2a gene therapy in heart failure: an anti-arrhythmic positive inotrope
    Sikkel, Markus B.
    Hayward, Carl
    MacLeod, Kenneth T.
    Harding, Sian E.
    Lyon, Alexander R.
    BRITISH JOURNAL OF PHARMACOLOGY, 2014, 171 (01) : 38 - 54
  • [40] Heterogeneous SERCA2a transfection reduces ventricular arrhythmias in the rat model of heart failure
    Lyon, Alexander
    Sepehripour, Amir
    Dubb, Sukhpreet
    Macleod, Ken
    Poole-Wilson, Philip
    Peters, Nicholas
    Harding, Sian
    JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 2008, 44 (04) : 714 - 715
12345